Reported about 11 hours ago
Despite recent setbacks, Pfizer is fostering a new partnership with Flagship Pioneering to develop innovative obesity treatments through Ampersand Biomedicines. This venture taps into a potentially lucrative weight loss drug market, estimated to reach $100 billion by 2030. However, while the collaboration is promising, investors are advised to be patient and wait for concrete developments before making purchasing decisions on Pfizer's stock.
Source: YAHOO